Market Overview:
The global tumor biomarker test market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The growth of the market can be attributed to the increasing incidence of cancer, technological advancements in tumor biomarker tests, and rising demand for personalized medicine. Based on type, the global tumor biomarker test market is segmented into prostate specific antigen tests, CTC tests, alpha-fetoprotein (AFP) tests, CA test, HER2 tests, BRCA test Anaplastic Lymphoma Kinase (ALK) Tests and EGFR mutation Tests. The prostate specific antigen (PSA) testing segment is expected to account for the largest share of the global tumor biomarker Test Market in 2018. This can be attributed to factors such as increasing incidence of prostate cancer and growing awareness about PSA testing among men. Based on application ,the lung cancer segment accounted for the largest share of the global tumor marker Test Market in 2017 .This can be attributedto factors such as high prevalenceof lung cancerand growing demandfor early detectionof lungcancer .
Product Definition:
A tumor biomarker test is a laboratory test that uses biomarkers to identify cancerous tumors. The importance of tumor biomarker tests is that they can help to diagnose cancer early, when it is easier to treat. Additionally, tumor biomarker tests can help doctors determine the best treatment plan for a particular patient.
Prostate Specific Antigen Tests:
Prostate specific antigen (PSA) is a protein produced by the prostate gland. PSA levels are generally higher in men with prostate cancer. However, elevated PSA levels do not necessarily mean that a man has cancer; it can also be found in some healthy men as well as some women after they have been pregnant and during hormonal changes leading to breast or cervical cancer.
CTC Tests:
CTC tests are also known as cell-based or biomarker testing. It is a process of identifying and measuring the level of certain proteins, hormones, enzymes, & other substances in cells or body fluids. CTC (Clinical Tumor Council) test is used to detect the presence of cancer cells in patients with suspected tumor.
Application Insights:
The application segment is segregated into lung cancer, breast cancer, colorectal cancer, prostate cancer, blood cancers and others. Breast Cancer was the largest revenue generating segment in 2017 owing to the growing number of women population suffering from breast tumor. Moreover, increasing awareness about early detection among women population is also expected to contribute towards market growth during the forecast period.
Global prostate specific antigen test (PSA) dominated the overall market in terms of revenue share in 2017 due to a large patient base and availability of various brands for testing at affordable prices.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, availability of advanced diagnostic techniques and high patient awareness levels coupled with relatively higher healthcare expenditure in this region as compared to other regions. The U.S.
Asia Pacific is expected to register lucrative growth during the forecast period due to increasing disposable income leading towards improved healthcare access especially in developing countries such as China & India thereby driving demand from various application areas including cancer diagnostics. Moreover, government initiatives encouraging R&D activities within Asia Pacific are also anticipated boost industry development over next eight years or so.
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for tumor biomarker test market. According to World Health Organization (WHO), cancer is the second leading cause of death, accounting for approximately 9 million deaths per year. This number is expected to rise to 13 million by 2030. Thus, there would be an increased demand for tumor biomarker tests in the coming years.
- Rising awareness about early detection and diagnosis: There is a growing awareness among people about the importance of early detection and diagnosis of cancer. This has led to an increase in demand for tumor biomarker tests, as they help in early detection and diagnosis of tumors.
- Technological advancements: The technological advancements in diagnostics are aiding the growth of tumor biomarker test market . For instance, next-generation sequencing (NGS) technology helps in identification and characterization of novel mutations associated with various cancers, which can be used as potential targets for treatment or prognosis purposes . This has resulted in an increase in adoption rateof NGS technology by diagnostic laboratories across the globe , thereby propellingthe growthof this market .
Scope Of The Report
Report Attributes
Report Details
Report Title
Tumor Biomarker Test Market Research Report
By Type
Prostate Specific Antigen Tests, CTC Tests, Alpha-Fetoprotein (AFP) Tests, CA Test, HER2 Tests, BRCA Test, Anaplastic Lymphoma Kinase (ALK) Tests, EGFR Mutation Tests, KRAS Test, Others
By Application
Lung cancer, Breast cancer, Colorectal, Prostate Cancer, Blood Cancer
By Companies
Abbott Laboratories, Inc., Agilent Technologies, AstraZeneca, Becton Dickinson & Co., Biocept Inc., Cancer Genetics Inc., Danaher Corporation, Foundation Medicine Inc., Illumina Inc., LabCorp Of America Holdings, Luminex Corporation, Myriad Genetics Inc., NanoString Technologies Inc.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
213
Number of Tables & Figures
150
Customization Available
Yes, the report can be customized as per your need.
Global Tumor Biomarker Test Market Report Segments:
The global Tumor Biomarker Test market is segmented on the basis of:
Types
Prostate Specific Antigen Tests, CTC Tests, Alpha-Fetoprotein (AFP) Tests, CA Test, HER2 Tests, BRCA Test, Anaplastic Lymphoma Kinase (ALK) Tests, EGFR Mutation Tests, KRAS Test, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Lung cancer, Breast cancer, Colorectal, Prostate Cancer, Blood Cancer
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Abbott Laboratories, Inc.
- Agilent Technologies
- AstraZeneca
- Becton Dickinson & Co.
- Biocept Inc.
- Cancer Genetics Inc.
- Danaher Corporation
- Foundation Medicine Inc.
- Illumina Inc.
- LabCorp Of America Holdings
- Luminex Corporation
- Myriad Genetics Inc.
- NanoString Technologies Inc.
Highlights of The Tumor Biomarker Test Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Prostate Specific Antigen Tests
- CTC Tests
- Alpha-Fetoprotein (AFP) Tests
- CA Test
- HER2 Tests
- BRCA Test
- Anaplastic Lymphoma Kinase (ALK) Tests
- EGFR Mutation Tests
- KRAS Test
- Others
- By Application:
- Lung cancer
- Breast cancer
- Colorectal
- Prostate Cancer
- Blood Cancer
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Tumor Biomarker Test Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
A tumor biomarker test is a type of medical test that can help doctors diagnose cancer. Tests that are used to detect tumor biomarkers include blood tests, imaging tests, and genetic tests. Tumor biomarkers may be specific to certain types of cancer or may be associated with other health problems.
Some of the major players in the tumor biomarker test market are Abbott Laboratories, Inc., Agilent Technologies, AstraZeneca, Becton Dickinson & Co., Biocept Inc., Cancer Genetics Inc., Danaher Corporation, Foundation Medicine Inc., Illumina Inc., LabCorp Of America Holdings, Luminex Corporation, Myriad Genetics Inc., NanoString Technologies Inc..
The tumor biomarker test market is expected to register a CAGR of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Tumor Biomarker Test Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Tumor Biomarker Test Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Tumor Biomarker Test Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Tumor Biomarker Test Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Tumor Biomarker Test Market Size & Forecast, 2020-2028
4.5.1 Tumor Biomarker Test Market Size and Y-o-Y Growth
4.5.2 Tumor Biomarker Test Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Prostate Specific Antigen Tests
5.2.2 CTC Tests
5.2.3 Alpha-Fetoprotein (AFP) Tests
5.2.4 CA Test
5.2.5 HER2 Tests
5.2.6 BRCA Test
5.2.7 Anaplastic Lymphoma Kinase (ALK) Tests
5.2.8 EGFR Mutation Tests
5.2.9 KRAS Test
5.2.10 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Lung cancer
6.2.2 Breast cancer
6.2.3 Colorectal
6.2.4 Prostate Cancer
6.2.5 Blood Cancer
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Tumor Biomarker Test Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Tumor Biomarker Test Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Prostate Specific Antigen Tests
9.6.2 CTC Tests
9.6.3 Alpha-Fetoprotein (AFP) Tests
9.6.4 CA Test
9.6.5 HER2 Tests
9.6.6 BRCA Test
9.6.7 Anaplastic Lymphoma Kinase (ALK) Tests
9.6.8 EGFR Mutation Tests
9.6.9 KRAS Test
9.6.10 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Lung cancer
9.10.2 Breast cancer
9.10.3 Colorectal
9.10.4 Prostate Cancer
9.10.5 Blood Cancer
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Prostate Specific Antigen Tests
10.6.2 CTC Tests
10.6.3 Alpha-Fetoprotein (AFP) Tests
10.6.4 CA Test
10.6.5 HER2 Tests
10.6.6 BRCA Test
10.6.7 Anaplastic Lymphoma Kinase (ALK) Tests
10.6.8 EGFR Mutation Tests
10.6.9 KRAS Test
10.6.10 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Lung cancer
10.10.2 Breast cancer
10.10.3 Colorectal
10.10.4 Prostate Cancer
10.10.5 Blood Cancer
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Prostate Specific Antigen Tests
11.6.2 CTC Tests
11.6.3 Alpha-Fetoprotein (AFP) Tests
11.6.4 CA Test
11.6.5 HER2 Tests
11.6.6 BRCA Test
11.6.7 Anaplastic Lymphoma Kinase (ALK) Tests
11.6.8 EGFR Mutation Tests
11.6.9 KRAS Test
11.6.10 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Lung cancer
11.10.2 Breast cancer
11.10.3 Colorectal
11.10.4 Prostate Cancer
11.10.5 Blood Cancer
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Prostate Specific Antigen Tests
12.6.2 CTC Tests
12.6.3 Alpha-Fetoprotein (AFP) Tests
12.6.4 CA Test
12.6.5 HER2 Tests
12.6.6 BRCA Test
12.6.7 Anaplastic Lymphoma Kinase (ALK) Tests
12.6.8 EGFR Mutation Tests
12.6.9 KRAS Test
12.6.10 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Lung cancer
12.10.2 Breast cancer
12.10.3 Colorectal
12.10.4 Prostate Cancer
12.10.5 Blood Cancer
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Prostate Specific Antigen Tests
13.6.2 CTC Tests
13.6.3 Alpha-Fetoprotein (AFP) Tests
13.6.4 CA Test
13.6.5 HER2 Tests
13.6.6 BRCA Test
13.6.7 Anaplastic Lymphoma Kinase (ALK) Tests
13.6.8 EGFR Mutation Tests
13.6.9 KRAS Test
13.6.10 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Lung cancer
13.10.2 Breast cancer
13.10.3 Colorectal
13.10.4 Prostate Cancer
13.10.5 Blood Cancer
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Tumor Biomarker Test Market: Competitive Dashboard
14.2 Global Tumor Biomarker Test Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Abbott Laboratories, Inc.
14.3.2 Agilent Technologies
14.3.3 AstraZeneca
14.3.4 Becton Dickinson & Co.
14.3.5 Biocept Inc.
14.3.6 Cancer Genetics Inc.
14.3.7 Danaher Corporation
14.3.8 Foundation Medicine Inc.
14.3.9 Illumina Inc.
14.3.10 LabCorp Of America Holdings
14.3.11 Luminex Corporation
14.3.12 Myriad Genetics Inc.
14.3.13 NanoString Technologies Inc.
